1. Home
  2. ADVM vs QSI Comparison

ADVM vs QSI Comparison

Compare ADVM & QSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • QSI
  • Stock Information
  • Founded
  • ADVM 2006
  • QSI 2013
  • Country
  • ADVM United States
  • QSI United States
  • Employees
  • ADVM N/A
  • QSI N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • QSI Biotechnology: Pharmaceutical Preparations
  • Sector
  • ADVM Health Care
  • QSI Health Care
  • Exchange
  • ADVM Nasdaq
  • QSI Nasdaq
  • Market Cap
  • ADVM 119.6M
  • QSI 633.2M
  • IPO Year
  • ADVM 2014
  • QSI N/A
  • Fundamental
  • Price
  • ADVM $4.25
  • QSI $2.03
  • Analyst Decision
  • ADVM Strong Buy
  • QSI Buy
  • Analyst Count
  • ADVM 6
  • QSI 2
  • Target Price
  • ADVM $27.83
  • QSI $3.25
  • AVG Volume (30 Days)
  • ADVM 217.5K
  • QSI 57.6M
  • Earning Date
  • ADVM 11-04-2024
  • QSI 02-27-2025
  • Dividend Yield
  • ADVM N/A
  • QSI N/A
  • EPS Growth
  • ADVM N/A
  • QSI N/A
  • EPS
  • ADVM N/A
  • QSI N/A
  • Revenue
  • ADVM $1,000,000.00
  • QSI $2,266,000.00
  • Revenue This Year
  • ADVM N/A
  • QSI $193.90
  • Revenue Next Year
  • ADVM $1,342.84
  • QSI $173.18
  • P/E Ratio
  • ADVM N/A
  • QSI N/A
  • Revenue Growth
  • ADVM N/A
  • QSI 232.26
  • 52 Week Low
  • ADVM $4.01
  • QSI $0.61
  • 52 Week High
  • ADVM $29.70
  • QSI $5.77
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 29.33
  • QSI 47.03
  • Support Level
  • ADVM $4.42
  • QSI $1.85
  • Resistance Level
  • ADVM $5.11
  • QSI $5.77
  • Average True Range (ATR)
  • ADVM 0.30
  • QSI 0.85
  • MACD
  • ADVM 0.01
  • QSI -0.14
  • Stochastic Oscillator
  • ADVM 21.05
  • QSI 17.62

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

About QSI Quantum-Si Incorporated

Quantum-Si Inc is focused on revolutionizing the growing field of proteomics. The company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond DNA sequencing.

Share on Social Networks: